M
Mohamad Sobh
Researcher at University of Lyon
Publications - 86
Citations - 1098
Mohamad Sobh is an academic researcher from University of Lyon. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 18, co-authored 86 publications receiving 982 citations. Previous affiliations of Mohamad Sobh include Lyon College.
Papers
More filters
Journal ArticleDOI
High burden of BK virus-associated hemorrhagic cystitis in patients undergoing allogeneic hematopoietic stem cell transplantation
Lila Gilis,Stephane Morisset,Geneviève Billaud,Sophie Ducastelle-Lepretre,Hélène Labussière-Wallet,Franck-Emmanuel Nicolini,Fiorenza Barraco,Marie Y. Detrait,Xavier Thomas,Nathalie Tedone,Mohamad Sobh,Christian Chidiac,Tristan Ferry,Gilles Salles,Mauricette Michallet,Florence Ader +15 more
TL;DR: Strategies to prevent the occurrence of late-onset BKV-HC after allo-HSCT are urgently needed, especially in CBU and peripheral blood stem cell recipients.
Journal ArticleDOI
Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from 2004 to 2009
Marie-Christine Nicolle,Thomas Bénet,Anne C. M. Thiébaut,Anne-Lise Bienvenu,Nicolas Voirin,Antoine Duclos,Mohamad Sobh,Giovanna Cannas,Xavier Thomas,Frank-Emmanuel Nicolini,Frédérique de Monbrison,Marie-Antoinette Piens,Stéphane Picot,Mauricette Michallet,Philippe Vanhems +14 more
TL;DR: Knowledge of invasive aspergillosis characteristics and its clinical course should help to improve the management of patients with severe disease and declined between 2004 and 2009.
Journal ArticleDOI
Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation
Mauricette Michallet,Peter Dreger,Laurent Sutton,Ronald Brand,Sue Richards,Marleen van Os,Mohamad Sobh,Sylvain Choquet,Bernadette Corront,Claire Dearden,Alois Gratwohl,Wolfgang Herr,Daniel Catovsky,Michael Hallek,Theo de Witte,Dietger Niederwieser,Michel Leporrier,Donald Milligan +17 more
TL;DR: In chronic lymphocytic leukemia, consolidating autografting reduces the risk of progression by more than 50% but has no effect on overall survival.
Journal ArticleDOI
High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma
Jean El-Cheikh,Mauricette Michallet,Arnon Nagler,Hugues de Lavallade,Franck E. Nicolini,Avichai Shimoni,Catherine Faucher,Mohamad Sobh,Daniela Revesz,Izhar Hardan,Sabine Furst,Didier Blaise,Mohamad Mohty +12 more
TL;DR: The estimate of overall survival was 65% at 18 months while this was significantly higher in the 27 patients achieving an objective response, suggesting that bortezomib is a safe and efficient option for myeloma patients after RIC-allo-SCT.
Journal ArticleDOI
Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties
Peter Dreger,Mauricette Michallet,Paul Bosman,Sascha Dietrich,Mohamad Sobh,Ariane Boumendil,Arnon Nagler,Christof Scheid,Jan J. Cornelissen,Dietger Niederwieser,Lutz P. Müller,Elizabeth Vandenberghe,Ilaria Scortechini,Hélène Schoemans,Niels Smedegaard Andersen,Jürgen Finke,Domenico Russo,Per Ljungman,Jakob Passweg,Michel van Gelder,Nadira Duraković,Hélène Labussière-Wallet,Tobias Berg,Gerald Wulf,Wolfgang Bethge,Donald Bunjes,Stefan Stilgenbauer,Maria Elisa Canepari,Michel Schaap,Christopher P. Fox,Nicolaus Kröger,Silvia Montoto,Johannes Schetelig +32 more
TL;DR: While the relatively high post-transplant relapse risk in ibrutinib-exposed patients with CLL deserves further study, in patients with MCL consolidating disease responses to ibrUTinib with alloHCT seems to be a promising option.